• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer

byJinny TsangandAlisha Yi
August 8, 2025
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in NEJM. 

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc.Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: Perioperative Durvalumab increased Survival in Gastric and Gastroesopha-geal Junction Cancer

#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

Tags: advanced breast cancerefficacyInavolisibPIK3CA-mutatedrctsafetysurvival
Previous Post

mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial

Next Post

Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease

RelatedReports

#VisualAbstract: Perioperative Durvalumab increased Survival in Gastric and Gastroesopha-geal Junction Cancer
StudyGraphics

#VisualAbstract: Perioperative Durvalumab increased Survival in Gastric and Gastroesopha-geal Junction Cancer

August 7, 2025
#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer
StudyGraphics

#VisualAbstract: 3-Year Structured Exercise after Adjuvant Chemotherapy Improved Survival for Colon Cancer

August 7, 2025
#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

July 18, 2025
#VisualAbstract: Obicetrapib Reduced LDL Cholesterol in Patients at High Cardiovascular Risk
StudyGraphics

#VisualAbstract: Obicetrapib Reduced LDL Cholesterol in Patients at High Cardiovascular Risk

July 15, 2025
Next Post
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

Ustekinumab may be superior to Vedolizumab for the treatment of Crohn's disease

Parental nonmedical prescription opioid use linked to adolescent use

Cervical medial branch blocks may offer therapeutic benefit for facet-mediated neck pain

Antiseizure medications do not reduce the risk of epilepsy in patients with brain abscess

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Antiseizure medications do not reduce the risk of epilepsy in patients with brain abscess
  • Cervical medial branch blocks may offer therapeutic benefit for facet-mediated neck pain
  • Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.